OSSIF-i sem

PreclinicalSmall molecule

LLoma Linda University

OSSIF-i sem is one of 4 small molecule programs targeting Bone Graft. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone GraftCompleted

Bone GraftPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Bone Graft

#DrugCompanyPhaseTrials

Xenograft

NNational University of Malaysia

Preclinical

1 2

Bioactive Glass

KKing Abdulaziz University

Preclinical

1 3

Bio-Oss

Daewoong Pharmaceutical Co. LTD.

Preclinical

1 4

OSSIF-i sem

LLoma Linda University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Graft1 trial

A Comparison of Bone Formation With Three Different Bone Graft Materials Following Sinus Graft

Completed·LLoma Linda University·N/A·NCT01911819·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OSSIF-i sem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OSSIF-i sem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OSSIF-i sem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Loma Linda University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLoma Linda University

OSSIF-i sem

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Graft1 trial

References

Drug Info

Quick Facts

Related News